AZD1940
Based on 1 publication(s) in Google Scholar
AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pKi values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.58%
- CAS. Nr.: 881413-29-2
- Formel: C20H29F2N3O2S
- Molecular Weight:413.52
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10013
TaranabantCB1 Receptor Invert Agonist -
HY-14137
Rimonabant HydrochlorideCB1 Antagonist -
HY-100488
Bay 59-3074CB1/CB2 Receptor Agonist -
HY-13505
AM281CB1 Antagonist -
HY-13288
Org 27569Cannabinoid Receptor Modulator -
HY-110179
PSNCBAM-1Cannabinoid Receptor Antagonist -
HY-110036
GW-405833CB2 Agonist -
HY-14136
Rimonabant -
HY-153800
MonlunabantCB1 Antagonist -
HY-18697
JD-5037CB1 Receptor Antagonist -
HY-107471
CB2 receptor agonist 3CB2 Receptor Agonist -
HY-121827
LH21CB1 Receptor Antagonist
Publications Citing Use of MedChemExpress (MCE) AZD1940
More
Biologische Aktivität
Beschreibung
IC50 & Target
[2]|
hCB1-R 7.93 (pKi) |
hCB2-R 9.06 (pKi) |
In Vitro
In Vivo
For AZD1940, low brain uptake at analgesic doses has been demonstrated in both rats and primates[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 881413-29-2
-
Appearance Solid
-
Molecular Weight 413.52
-
Formel C20H29F2N3O2S
-
Color White to off-white
-
SMILES
CCS(=O)(NC1=CC=C2C(N=C(C(C)(C)C)N2CC3CCC(F)(F)CC3)=C1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Genetically Encoded CB2R-Based Fluorescent Sensor Enables Rapid Screening and Functional Assessment of Cannabinoid Modulators. [Abstract]2026 Feb 24;27(5):2095. PMID: 41828327
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (241.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Jarkko Kalliomäki, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013 Mar;40(3):212-8. [Content Brief]
[2]. Magnus Schou, et al. Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. Nucl Med Biol. 2013 Apr;40(3):410-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4183 mL | 12.0913 mL | 24.1826 mL | 60.4566 mL |
| 5 mM | 0.4837 mL | 2.4183 mL | 4.8365 mL | 12.0913 mL | |
| 10 mM | 0.2418 mL | 1.2091 mL | 2.4183 mL | 6.0457 mL | |
| 15 mM | 0.1612 mL | 0.8061 mL | 1.6122 mL | 4.0304 mL | |
| 20 mM | 0.1209 mL | 0.6046 mL | 1.2091 mL | 3.0228 mL | |
| 25 mM | 0.0967 mL | 0.4837 mL | 0.9673 mL | 2.4183 mL | |
| 30 mM | 0.0806 mL | 0.4030 mL | 0.8061 mL | 2.0152 mL | |
| 40 mM | 0.0605 mL | 0.3023 mL | 0.6046 mL | 1.5114 mL | |
| 50 mM | 0.0484 mL | 0.2418 mL | 0.4837 mL | 1.2091 mL | |
| 60 mM | 0.0403 mL | 0.2015 mL | 0.4030 mL | 1.0076 mL | |
| 80 mM | 0.0302 mL | 0.1511 mL | 0.3023 mL | 0.7557 mL | |
| 100 mM | 0.0242 mL | 0.1209 mL | 0.2418 mL | 0.6046 mL |
AZD1940 Related Classifications
HY-119104 Related Classifications
Powered by Bioz